EGFR and lung adenocarcinoma: Herein, we aimed to develop and interpret robust optimal predictive models to identify EGFR mutation status and subtypes based on multi-center 18F-FDG PET/CT data, and further construct a prognostic model to predict clinical outcome in patients with lung adenocarcinoma.